Access the full text.
Sign up today, get DeepDyve free for 14 days.
Zhong Wang, T. Bhattacharyya (2010)
Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996–2007Journal of Bone and Mineral Research, 26
F. Hsiao, Weng‐Foung Huang, Yi-Ming Chen, Y. Wen, Y. Kao, Liang‐Kung Chen, Y. Tsai (2011)
Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.Clinical therapeutics, 33 11
K. Armstrong, M. Berlin, J. Schwartz, K. Propert, P. Ubel (2001)
Barriers to influenza immunization in a low-income urban population.American journal of preventive medicine, 20 1
E. Amine, N. Baba, M. Belhadj, M. Deurenberg-Yap, A. Djazayery, T. Forrestre, D. Galuska, S. Herman, James Wpt, J. Kabangu, M. Katan, T. Key, S. Kumanyika, J. Mann, P. Moynihan, A. Musaiger, G. Olwit, J. Petkevičienė, A. Prentice, K. Reddy, A. Schatzkin, J. Seidell, A. Simopoulos, S. Srianujata, N. Steyn, B. Swinburn, R. Uauy, M. Wahlqvist, W. Zhao-su, N. Yoshiike, S. Rabenek, K. Bagchi, T. Cavalli-Sforza, G. Clugston, I. Darnton-Hill, A. Ferro-Luzzi, J. Leowski, C. Nishida, D. Nyamwaya, A. Ouedraogo, P. Pietinen, P. Puska, E. Riboli, A. Robertson, P. Shetty, R. Weisell, D. Yach (2003)
Diet, nutrition and the prevention of chronic diseases
J. Higgins, D. Altman, P. Gøtzsche, P. Jüni, D. Moher, A. Oxman, J. Savović, K. Schulz, L. Weeks, J. Sterne (2011)
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsThe BMJ, 343
N. Napoli, A. Schwartz, L. Palermo, Jenny Jin, R. Wustrack, J. Cauley, K. Ensrud, M. Kelly, D. Black (2013)
Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures.The Journal of clinical endocrinology and metabolism, 98 2
C. Odvina, J. Zerwekh, D. Rao, N. Maalouf, F. Gottschalk, C. Pak (2005)
Severely suppressed bone turnover: a potential complication of alendronate therapy.The Journal of clinical endocrinology and metabolism, 90 3
Russell Harris, M. Helfand, S. Woolf, K. Lohr, C. Mulrow, S. Teutsch, D. Atkins (2001)
Current methods of the US Preventive Services Task Force: a review of the process.American journal of preventive medicine, 20 3 Suppl
R. Meier, T. Perneger, R. Stern, R. Rizzoli, R. Peter (2012)
Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.Archives of internal medicine, 172 12
J. Schilcher, K. Michaëlsson, P. Aspenberg (2011)
Bisphosphonate use and atypical fractures of the femoral shaft.The New England journal of medicine, 364 18
R. Dersimonian, R. Dersimonian, N. Laird, N. Laird (1986)
Meta-analysis in clinical trials.Controlled clinical trials, 7 3
L. Park-Wyllie, M. Mamdani, D. Juurlink, G. Hawker, N. Gunraj, P. Austin, D. Whelan, P. Weiler, A. Laupacis (2011)
Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.JAMA, 305 8
J. Erviti, Á. Alonso, B. Oliva, J. Gorricho, Antonio López, J. Timoner, C. Huerta, M. Gil, F. Abajo (2013)
Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case–control studyBMJ Open, 3
D. Black, Michael Kelly, H. Genant, L. Palermo, R. Eastell, C. Bucci-Rechtweg, J. Cauley, P. Leung, S. Boonen, A. Santora, A. Papp, D. Bauer (2010)
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.The New England journal of medicine, 362 19
D. Black, P. Delmas, R. Eastell, I. Reid, S. Boonen, J. Cauley, F. Cosman, P. Lakatos, P. Leung, Z. Man, C. Mautalen, P. Mesenbrink, Huilin Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T. Hue, D. Sellmeyer, E. Eriksen, S. Cummings (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.The New England journal of medicine, 356 18
M. Egger, G. Smith, Martin Schneider, C. Minder (1997)
Bias in meta-analysis detected by a simple, graphical testBMJ, 315
P. Vestergaard, F. Schwartz, Lars Rejnmark, Le. Mosekilde (2011)
Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifeneOsteoporosis International, 22
S. Cummings, D. Black, D. Thompson, W. Applegate, E. Barrett-Connor, T. Musliner, L. Palermo, R. Prineas, S. Rubin, J. Scott, T. Vogt, R. Wallace, A. Yates, A. LaCroix (1998)
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.JAMA, 280 24
D. Black, S. Cummings, D. Karpf, J. Cauley, D. Thompson, M. Nevitt, D. Bauer, H. Genant, W. Haskell, R. Marcus, S. Ott, J. Torner, S. Quandt, T. Reiss, K. Ensrud (1996)
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 348
S. Sanderson, I. Tatt, J. Higgins (2007)
Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography.International journal of epidemiology, 36 3
B. Abrahamsen, P. Eiken, R. Eastell (2009)
Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register‐Based National Cohort StudyJournal of Bone and Mineral Research, 24
D. Black, A. Schwartz, K. Ensrud, J. Cauley, S. Levis, S. Quandt, S. Satterfield, R. Wallace, D. Bauer, L. Palermo, L. Wehren, A. Lombardi, A. Santora, S. Cummings (2006)
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.JAMA, 296 24
E. Shane, D. Burr, B. Abrahamsen, R. Adler, T. Brown, A. Cheung, F. Cosman, J. Curtis, R. Dell, D. Dempster, P. Ebeling, T. Einhorn, H. Genant, P. Geusens, K. Klaushofer, J. Lane, F. McKiernan, Ross McKinney, A. Ng, J. Nieves, R. O’Keefe, S. Papapoulos, T. Howe, M. Meulen, R. Weinstein, M. Whyte (2011)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 29
B. Abrahamsen, P. Eiken, R. Eastell (2010)
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.The Journal of clinical endocrinology and metabolism, 95 12
Brett Lenart, Brett Lenart, Andrew Neviaser, Andrew Neviaser, S. Lyman, Charles Chang, Charles Chang, F. Edobor-Osula, F. Edobor-Osula, B. Steele, B. Steele, Marjolein Meulen, D. Lorich, D. Lorich, Joseph Lane, J. Lane (2009)
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control studyOsteoporosis International, 20
D. Sellmeyer (2010)
Atypical fractures as a potential complication of long-term bisphosphonate therapy.JAMA, 304 13
AbstractBackground:Studies suggest an increasing occurrence of atypical femoral fractures with the use of bisphosphonates.Objective:To examine whether the use of bisphosphonates increases the risk for atypical fractures.Design:Systematic review and meta-analysis.Data Sources:Literature search of MEDLINE, Embase and Cochrane CENTRAL (1948–June 2013).Review Methods:Selection criteria: (i) randomized controlled trial or an observational study, (ii) evaluated bisphosphonate therapy versus no treatment and (iii) reported an incidence of subtrochanteric or diaphyseal fracture individually, or a composite of both. Two independent investigators completed study selection, data extraction and validity assessment. The Cochrane Risk of Bias Tool was used to assess the quality of included studies.Results:Ten (n = 658497) studies were included in the meta-analysis which demonstrated a statistically significant increased risk of subtrochanteric or diaphyseal fracture with bisphosphonate use [adjusted odds ratios (AOR) = 1.99, 95% confidence intervals (CI)= 1.28–3.10] with I2 = 84.3% (95% CI = 73.5%–89.5%) and Egger P = 0.01. Subtrochanteric fractures showed an AOR = 2.71 (95% CI = 1.86–3.95) with I2 = 83.6% (95% CI = 64.3%–90.3%) and Egger’s P = 2.29. Diaphyseal fractures had an AOR = 2.06 (95% CI = 1.70–2.50), I2 = 29.7% (95% CI = 0%–73.7%) and Egger’s P = 1.22.Conclusion:Results suggest there is an increased risk for atypical fractures associated with bisphosphonates and raises awareness to the potential complications related with bisphosphonates. These findings warrant the comprehensive evaluation of patients before initiating bisphosphonate therapy and highlights the need for additional medical decision analyses in future studies to compare the benefit over potential harms of bisphosphonate therapy.
Family Practice – Oxford University Press
Published: Jun 1, 2015
Keywords: Key words: Osteoporosis prevention primary care risk assessment.
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.